Position in URGN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$647,128
New position
Shares Held
17,585
first reported quarter
Ownership
0.036%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#92
of 190 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026CAPITAL FUND MANAGEMENT S.A. holds $326,278,392 across 42 Biotechnology names. URGN ranks #38 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
155,904 | $46,931,781 | |
| 2 | INCY |
Incyte Corp
|
336,318 | $38,125,008 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
71,088 | $35,311,542 | |
| 4 | EXEL |
Exelixis, Inc.
|
527,235 | $28,686,856 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
329,554 | $26,130,336 | |
| 6 | MRNA |
Moderna, Inc.
|
277,758 | $19,451,392 | |
| 7 | CORT |
Corcept Therapeutics Inc
|
184,231 | $16,018,885 | |
| 8 | INSM |
INSMED Inc
|
148,976 | $15,883,821 |
All Filings in URGN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $647,128 | 17,585 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||